{
  "id": "resp_05ee0a104c47b26900693c9590b7888195b5cf1c3942f23b43",
  "object": "response",
  "created_at": 1765578128,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_05ee0a104c47b26900693c9590f57881958b602302eea8e5bc",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_05ee0a104c47b26900693c9591d79c8195bfcfbb5881bcafb1",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"CDK12\" \"molecular glue\" degrader press release"
      }
    },
    {
      "id": "rs_05ee0a104c47b26900693c959376cc8195998e8f790fd90a90",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_05ee0a104c47b26900693c959516b88195b667663b99928196",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:businesswire.com CDK12 molecular glue"
      }
    },
    {
      "id": "rs_05ee0a104c47b26900693c9596983c8195bbf6d408775a4943",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_05ee0a104c47b26900693c95995ef48195ae0573b7eb8d9187",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Cyclin-K\" \"glue degrader\" press release"
      }
    },
    {
      "id": "rs_05ee0a104c47b26900693c959b93fc8195b6772f4b609c208d",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_05ee0a104c47b26900693c959e2c408195997134b5e95dfbbf",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
      }
    },
    {
      "id": "rs_05ee0a104c47b26900693c959fb15c819594c8a8f12d4fbbdb",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_05ee0a104c47b26900693c95a6400c8195a0e9064ecf813f9c",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "NCT06600789 CT7439"
      }
    },
    {
      "id": "rs_05ee0a104c47b26900693c95a8ea548195b88da56e757fa4c5",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_05ee0a104c47b26900693c95a9362081958c00699caa746ab3",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "clinicaltrials.gov \"NCT06600789\" CT7439 CDK12/13"
      }
    },
    {
      "id": "rs_05ee0a104c47b26900693c95ad4df48195971db2bcb340f96e",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_05ee0a104c47b26900693c95adda588195a7326a9eadff0242",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://clinicaltrials.gov/study/NCT06600789"
      }
    },
    {
      "id": "rs_05ee0a104c47b26900693c95aefefc81958badb2077845dcf4",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_05ee0a104c47b26900693c95b7bcf081958af1dc91a46f1229",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/"
      }
    },
    {
      "id": "rs_05ee0a104c47b26900693c95ba05088195b4d2607e6a0742b5",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_05ee0a104c47b26900693c95c4b1b48195ac3a05182e91e895",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [
            {
              "type": "url_citation",
              "end_index": 598,
              "start_index": 438,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.",
              "url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
            },
            {
              "type": "url_citation",
              "end_index": 863,
              "start_index": 703,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.",
              "url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
            },
            {
              "type": "url_citation",
              "end_index": 1102,
              "start_index": 942,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.",
              "url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
            },
            {
              "type": "url_citation",
              "end_index": 1826,
              "start_index": 1626,
              "title": "Carrick Therapeutics Announces U.S. FDA Clearance of IND",
              "url": "https://www.globenewswire.com/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html"
            },
            {
              "type": "url_citation",
              "end_index": 2111,
              "start_index": 1911,
              "title": "Carrick Therapeutics Announces U.S. FDA Clearance of IND",
              "url": "https://www.globenewswire.com/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html"
            },
            {
              "type": "url_citation",
              "end_index": 2390,
              "start_index": 2190,
              "title": "Carrick Therapeutics Announces U.S. FDA Clearance of IND",
              "url": "https://www.globenewswire.com/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html"
            },
            {
              "type": "url_citation",
              "end_index": 3112,
              "start_index": 2912,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase",
              "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html"
            },
            {
              "type": "url_citation",
              "end_index": 3437,
              "start_index": 3237,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase",
              "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html"
            },
            {
              "type": "url_citation",
              "end_index": 3669,
              "start_index": 3469,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase",
              "url": "https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html"
            },
            {
              "type": "url_citation",
              "end_index": 4000,
              "start_index": 3919,
              "title": "\n\n    \n        Trial | NCT06600789\n    \n\n",
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/"
            },
            {
              "type": "url_citation",
              "end_index": 4168,
              "start_index": 4087,
              "title": "\n\n    \n        Trial | NCT06600789\n    \n\n",
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/"
            },
            {
              "type": "url_citation",
              "end_index": 4293,
              "start_index": 4212,
              "title": "\n\n    \n        Trial | NCT06600789\n    \n\n",
              "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/"
            }
          ],
          "logprobs": [],
          "text": "- **Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)**  \n  **URL:** `https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase`  \n  **Direct quote snippets (identifiers/targets/modalities/indications):**  \n  > “CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor / Cyclin-K glue-degrader.” ([carricktherapeutics.com](https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase))  \n  > “Clinical trial details can also be found on www.clinicaltrials.gov under study ID: NCT06600789.” ([carricktherapeutics.com](https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase))  \n  > “advanced solid tumors, including ovarian, breast and Ewing's Sarcoma.” ([carricktherapeutics.com](https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase))  \n\n- **Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13**  \n  **URL:** `https://www.globenewswire.com/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html`  \n  **Direct quote snippets (identifiers/targets/modalities/indications):**  \n  > “the Company’s Investigational New Drug (IND) application for CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor.” ([globenewswire.com](https://www.globenewswire.com/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html))  \n  > “CT7439 is an inhibitor of CDK12/13 as well as a 'glue degrader' of Cyclin-K” ([globenewswire.com](https://www.globenewswire.com/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html))  \n  > “advanced solid tumors, including breast, ovarian and Ewing's Sarcoma.” ([globenewswire.com](https://www.globenewswire.com/news-release/2023/09/07/2739242/0/en/Carrick-Therapeutics-Announces-U-S-FDA-Clearance-of-IND-for-CT7439-a-First-In-Class-Inhibitor-of-CDK12-13.html))  \n\n- **Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)**  \n  **URL:** `https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html`  \n  **Direct quote snippets (identifiers/targets/modalities/indications):**  \n  > “Phase 1 clinical trial evaluating CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor / Cyclin-K glue-degrader.” ([globenewswire.com](https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html))  \n  > “The clinical trial is enrolling patients with advanced solid tumors, including ovarian, breast and Ewing's Sarcoma.” ([globenewswire.com](https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html))  \n  > “study ID: NCT06600789.” ([globenewswire.com](https://www.globenewswire.com/news-release/2024/09/23/2951333/0/en/Carrick-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-CT7439-CDK12-13-Inhibitor.html))  \n\n- **Trial | NCT06600789 (Clinical Drug Experience Knowledgebase, Purdue)**  \n  **URL:** `https://cdek.pharmacy.purdue.edu/trial/NCT06600789/`  \n  **Direct quote snippets (identifiers/targets/modalities/indications):**  \n  > “Trial | NCT06600789” ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT06600789/))  \n  > “A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies” ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT06600789/))  \n  > “CT7439 Capsules (0.5 mg, 1mg, 3mg)” ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT06600789/))"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "medium",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 32851,
    "input_tokens_details": {
      "cached_tokens": 4352
    },
    "output_tokens": 3883,
    "output_tokens_details": {
      "reasoning_tokens": 3004
    },
    "total_tokens": 36734
  },
  "user": null,
  "metadata": {}
}